KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Shares Outstanding (2016 - 2025)

Exact Sciences (EXAS) has disclosed Shares Outstanding for 16 consecutive years, with $190.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 2.79% to $190.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $190.8 million through Dec 2025, up 2.79% year-over-year, with the annual reading at $190.8 million for FY2025, 2.79% up from the prior year.
  • Shares Outstanding for Q4 2025 was $190.8 million at Exact Sciences, up from $189.5 million in the prior quarter.
  • The five-year high for Shares Outstanding was $190.8 million in Q4 2025, with the low at $171.3 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $180.8 million, with a median of $180.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding increased 14.62% in 2021, then grew 1.93% in 2023.
  • Over 5 years, Shares Outstanding stood at $173.7 million in 2021, then increased by 2.45% to $177.9 million in 2022, then grew by 1.93% to $181.4 million in 2023, then rose by 2.34% to $185.6 million in 2024, then rose by 2.79% to $190.8 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $190.8 million, $189.5 million, and $189.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.